This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

NRx Pharmaceuticals (NASDAQ: NRXP) , a clinical-stage biopharmaceutical company, is executing a dual growth strategy focused on expanding its nationa ...

To view the full article, visit https://ibn.fm/TqKn4 ...

People who receive six or more prescriptions of gabapentin for lower back pain are at a significantly higher risk of dementia and mild cognitive impairment, a large new study suggests.

Do you remember the COVID-19 shutdowns? Many Americans could no longer do the activities they enjoyed once businesses, schools, churches, gyms and community organizations shut their doors. Even ...

Rexulti, which is used to treat depression and other conditions, can cause side effects. Learn about its mild and serious side effects and how to manage them.

Akathisia is a movement disorder associated with antipsychotics and characterized by a feeling of restlessness and a need to be in constant motion.

Is it akathisia?” asks the digital billboard, its bold white letters etched against a scrubs-blue sky—the color of calm and care—like a diagnosis writ large on the highway of denial. “Akathisia: an ...

Detailed price information for Nrx Pharmaceuticals Inc (NRXP-Q) from The Globe and Mail including charting and trades.

Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all lines are in a listen-only mode.

NRX-101 continues to progress toward NDA filing for Accelerated Approval in patients with bipolar depression and suicidality or akathisia. The filing is expected to be based on based on the strong ...

--NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2024, and provided a business update. We ...